百诚医药：BIOS2242口服溶液获得临床试验批准

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution, intended for the treatment of mild to moderate acute ischemic stroke [1] Group 1 - The clinical trial application for BIOS2242 oral solution was accepted on August 27, 2025, and has met the requirements for drug registration [1] - The approved clinical trial will focus on the indication of treating mild to moderate acute ischemic stroke [1]